Patent ID: 11946927
Assignee: nan
Field: Pharmaceuticals (Chemistry)
Classification: CPC G  A  Y | IPC A  G

Claim 0:
1. A process of predicting an individual's risk of developing inflammatory bowel disease (IBD) and treating the individual that has a risk of developing IBD, the process comprises the steps of:
selecting an individual to be tested prior to the individual showing symptoms of IBD such that the individual would be diagnose with having IBD;
obtaining a first blood sample of the selected individual;
examining the blood sample to obtain a level of each predictive target biomarker listed in a prediction panel of predictive target biomarkers;
determining the total level of protein in the blood sample;
using a prediction logistic regression model that uses the predictive target biomarkers listed in the prediction panel of predictive target biomarkers for predicting the risk of an individual developing IBD and using the logistic regression model and the levels of each predictive target biomarker and the total level of protein in the blood sample to calculate a risk value for the selected individual developing IBD; and
determining if the risk value for the selected individual developing IBD is above or below a cut-off value for the prediction logistic regression model;
wherein the prediction panel of predictive target biomarkers for use in predicting the risk of an individual developing IBD comprises the predictive target biomarkers of Haptoglobin (HP), Granulocyte Colony Stimulating Factor (GCSF), Resistin (RETN), C-Reactive Protein (CRP), Soluble Interacellular Adhesion Molecule 1 (sICAM1) and Antibody TT and identifies the relationships of sICAM1×HP, GCSF×CRP and GCSF×RETN;
wherein the prediction logistic regression model for determining the risk value for an individual developing IBD is: Log (p/1ip)=−641.8833706+71.65755693×HP−41.87442414×GCSF−45.27490174×RETN−16.22723673×CRP−1.029456032×Antibody TT+14.476981343×sICAM1+5.667294456×(sICAM1×HP)−0.80715758×(GCSF×CRP)−2.288843531×(GCSF×RETN), wherein the cut-off value of is 0.68;
wherein if the determined risk value for the selected individual developing IBD is greater than the cut-off value for the prediction logistic regression model, the process includes administering a therapy to the selected individual to reduce the risk of the selected individual developing IBD, wherein said therapy includes administering a medication for treating IBD, repeating the process of determining the risk value for the selected individual developing IBD, wherein if the risk value increases or remains the same, making modifications to the therapy being administered to the selected individual and repeating the process of determining the risk value for the selected individual developing IBD; and
continue the therapy or continue to modify the therapy until the risk value for the selected individual developing IBD is below the cut-off value for the prediction logistic regression model; and
wherein if the risk value for the selected individual developing IBD is below the cut-off value for the prediction logistic regression model used for determining the risk value of an individual developing IBD, the process includes using Disease Factors of the selected individual to determine if the process is to be performed again at a future date or administer a therapy to the selected individual when the selected individual is diagnosed with IBD, Crohn's disease or UC for treating IBD, Crohn's disease or UC.